Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 4 stocks made the list for top value stocks in the Life Sciences Tools & Services industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.
Why Focus on Undervalued Life Sciences Tools & Services Stocks?
Value investors seek to buy stocks at a discount to their intrinsic value. Long-term returns show that such strategies are advantageous. Value stocks, as a group, tend to outperform growth stocks over extended periods of time. Typically, value investors perform financial analysis of numerous metrics, don’t follow the herd and are long-term investors.
AAII’s A+ Investor Value Grade is derived from a stock’s Value Score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.
What Goes Into AAII’s Value Grade?
Stock evaluation requires access to huge amounts of data as well as the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movement. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors with that task.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A–F grades for more than just value. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others. Some stocks may even have null values for certain metrics like the price-earnings ratio or the price-to-book ratio but not others. An example of this would be a company with losses instead of profits or a negative book value because of heavy borrowing. Negative earnings or book value result in non-meaningful ratios that are left blank or null.
Click the button below to learn more about A+ Investor and subscribe today.
4 Undervalued Life Sciences Tools & Services Stocks
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued stocks in the Life Sciences Tools & Services industry for Thursday, February 19, 2026. Let’s take a closer look at their individual scores to see how they measure up against each other and the Life Sciences Tools & Services industry median.
| Company | Ticker | Price/Sales | Price/Earnings | EV/EBITDA | Shareholder Yield | Price/Book Value | Price/Free Cash Flow | Value Grade |
| Bio-Rad Laboratories, Inc. | BIO | 2.88 | 9.7 | 17.9 | 3.6% | 0.98 | 19.7 | B |
| Cytek Biosciences, Inc. | CTKB | 2.76 | na | na | 2.6% | 1.42 | na | B |
| Cryoport, Inc. | CYRX | 1.75 | na | na | (1.4%) | 0.91 | na | B |
| Fortrea Holdings Inc. | FTRE | 0.34 | na | na | (1.8%) | 1.66 | na | B |
The Value Grade is assigned based on how each stock’s composite valuation compares to all other stocks.
The process for assigning grades starts with each variable for a given stock. The percentile rankings for all valid ratios that a stock has are calculated. So, for instance, a stock could have a price-to-book ranking in the 43rd percentile, a price-earnings ranking in the 67th percentile, a price-to-sales ranking in the 23rd percentile, etc. Then, those rankings are averaged for each stock. (A minimum of two valid variables are required, though all six will be used if available.)
Once the average of the individual variables is calculated, that average is ranked against all stocks. Put another way, each stock’s composite valuation is compared to all other stocks. These ranks are then sorted into quintiles from the cheapest 20% (a grade of A) to the most expensive 20% (a grade of F).
As always, we recommend that you conduct proper due diligence and research before investing in any security. We also suggest that investors utilize numerous grades, not just value, when it comes to deciding whether a company is a good fit for their allocation needs.
Bio-Rad Laboratories, Inc.’s Value Grade
Value Grade:
| Metric | Score | BIO | Industry Median |
| Price/Sales | 60 | 2.88 | 2.79 |
| Price/Earnings | 14 | 9.7 | 29.9 |
| EV/EBITDA | 70 | 17.9 | 19.3 |
| Shareholder Yield | 22 | 3.6% | (1.4%) |
| Price/Book Value | 23 | 0.98 | 2.14 |
| Price/Free Cash Flow | 49 | 19.7 | 24.4 |
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Bio-Rad Laboratories, Inc. has a Value Score of 65, which is considered to be undervalued.
When you look at Bio-Rad Laboratories, Inc.’s price-to-sales ratio at 2.88 compared to the industry median at 2.79, this company has a higher price relative to revenue compared to its peers. This could make Bio-Rad Laboratories, Inc.’s stock less attractive for value investors.
Bio-Rad Laboratories, Inc.’s price-earnings ratio is 9.70 compared to the industry median at 29.90. This means it has a lower share price relative to earnings compared to its peers. This could make Bio-Rad Laboratories, Inc. more attractive for value investors.
Now, let’s assess Bio-Rad Laboratories, Inc.’s EV/EBITDA ratio, also known as enterprise multiple. At 17.9, when compared to the industry median of 19.3, the company may be considered undervalued in relation to its peers. Value investors could use the enterprise multiple to identify stocks that are considered overvalued or undervalued relative to their industry.
Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. Bio-Rad Laboratories, Inc.’s shareholder yield is higher than its industry median ratio of (1.40%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.
As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. Bio-Rad Laboratories, Inc.’s price-to-book ratio is lower than its industry median ratio of 2.14. This could make Bio-Rad Laboratories, Inc. more attractive to investors looking for a new addition to their portfolio.
Lastly, let’s take a look at Bio-Rad Laboratories, Inc.’s price-to-free-cash-flow ratio (P/FCF), which can indicate a company’s market value relative to its operating cash flow. Bio-Rad Laboratories, Inc.’s price-to-free-cash-flow ratio is lower than its industry median ratio of 24.40. This could make Bio-Rad Laboratories, Inc. more attractive because the lower P/FCF ratio indicates that Bio-Rad Laboratories, Inc. is undervalued. The P/FCF ratio metric can also be viewed over a long-term time frame to see if the company's cash flow to share price value is generally improving or worsening.
Cytek Biosciences, Inc.’s Value Grade
Value Grade:
| Metric | Score | CTKB | Industry Median |
| Price/Sales | 59 | 2.76 | 2.79 |
| Price/Earnings | na | na | 29.9 |
| EV/EBITDA | na | na | 19.3 |
| Shareholder Yield | 27 | 2.6% | (1.4%) |
| Price/Book Value | 38 | 1.42 | 2.14 |
| Price/Free Cash Flow | na | na | 24.4 |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Cytek Biosciences, Inc. has a Value Score of 62, which is considered to be undervalued.
Cytek Biosciences, Inc.’s price-to-book ratio is higher than its peers. This could make Cytek Biosciences, Inc. less attractive for value investors when compared to the industry median at 2.14.
You can read more about Cytek Biosciences, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Cryoport, Inc.’s Value Grade
Value Grade:
| Metric | Score | CYRX | Industry Median |
| Price/Sales | 46 | 1.75 | 2.79 |
| Price/Earnings | na | na | 29.9 |
| EV/EBITDA | na | na | 19.3 |
| Shareholder Yield | 59 | (1.4%) | (1.4%) |
| Price/Book Value | 20 | 0.91 | 2.14 |
| Price/Free Cash Flow | na | na | 24.4 |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions’ Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Cryoport, Inc. has a Value Score of 61, which is considered to be undervalued.
Cryoport, Inc.’s price-to-book ratio is higher than its peers. This could make Cryoport, Inc. less attractive for value investors when compared to the industry median at 2.14.
You can read more about Cryoport, Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Fortrea Holdings Inc.’s Value Grade
Value Grade:
| Metric | Score | FTRE | Industry Median |
| Price/Sales | 14 | 0.34 | 2.79 |
| Price/Earnings | na | na | 29.9 |
| EV/EBITDA | na | na | 19.3 |
| Shareholder Yield | 61 | (1.8%) | (1.4%) |
| Price/Book Value | 44 | 1.66 | 2.14 |
| Price/Free Cash Flow | na | na | 24.4 |
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. The company has a strategic collaboration with SCT Cell Manufacturing s.r.o. to streamline development, accelerate timelines and bring advanced therapies to patients faster. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.
Fortrea Holdings Inc. has a Value Score of 65, which is considered to be undervalued.
Fortrea Holdings Inc.’s price-to-book ratio is higher than its peers. This could make Fortrea Holdings Inc. less attractive for value investors when compared to the industry median at 2.14.
You can read more about Fortrea Holdings Inc.’s key financial metrics like shareholder yield, price-to-free-cash-flow and EV/EBITDA ratio, or learn more about its Momentum and Growth Grades, by subscribing to A+ Investor.
Other Life Sciences Tools & Services Stock Grades
Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate revisions and quality—on the A+ Stock Grades Screener.
Also, if you want full access to all of AAII’s premium services, you can subscribe to one convenient bundled plan called AAII Platinum where you can try out A+ Investor, AAII Dividend Investing, the Stock Superstars Report, Growth Investing and VMQ Stocks. With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Life Sciences Tools & Services stocks as well as other industrys.
Choosing Which of the 4 Best Life Sciences Tools & Services Stocks Is Right for You
Choosing which value stocks to invest in will ultimately depend on your individual goals and allocation; however, comparing similar value stocks in the same industry can help you analyze which might be better investments for you in the long run. So, let’s take a look at the Value Grade for all of our stocks.
- Bio-Rad Laboratories, Inc. stock has a Value Grade of B.
- Cytek Biosciences, Inc. stock has a Value Grade of B.
- Cryoport, Inc. stock has a Value Grade of B.
- Fortrea Holdings Inc. stock has a Value Grade of B.
Now that you have a bit more background about each of the 4 undervalued stocks in the Life Sciences Tools & Services industry as well as their overall grades, it’s time for you to conduct additional research to see if these could fit your portfolio needs based on your goals and risk tolerance. AAII can help you figure out both and identify which investments align with what works best for you.
We do so through a program of education that teaches you to invest for yourself and become an effective manager of your own wealth—no more relying on others for your financial independence. You can rely on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis that makes you a better investor.
A+ Investor adds to that qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.
Additional Resources About Life Sciences Tools & Services Stocks
Want to learn more about Life Sciences Tools & Services stocks to see if they could be the right investment for you? Check out some additional resources and articles to help you on your financial journey.
- 4 Undervalued Life Sciences Tools & Services Stocks for Thursday, February 19
- Is Danaher Corporation (DHR) Overvalued?
- Is Thermo Fisher Scientific Inc. (TMO) Overvalued?
- Is Danaher Corporation (DHR) Overvalued?
AAII Disclaimer
We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith and we accept no liability for any errors or omissions. The full disclaimer can be read here.
Included With AAII Platinum
at only 6.9%
Since Inception. Data as of 12/31/2024.
769.3% Stock Superstars Portfolio Total Return Since Inception
U.S. Index ETF (IYY)
SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.
FREE REPORT
BECOME A MEMBER FOR ONLY $2
Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.